Aug 4, 2026 7:00 am EDT iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
Jul 1, 2026 7:00 am EDT iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
Jun 2, 2026 7:00 am EDT iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
May 12, 2026 4:05 pm EDT iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
May 8, 2026 7:15 am EDT iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
Apr 8, 2026 7:00 am EDT iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
Mar 16, 2026 4:30 pm EDT iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Mar 9, 2026 7:00 am EDT iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss